# Ipamorelin Research: Mechanism, Body Composition, and the Study Record > Ipamorelin research digest: the GHS-R1a mechanism, the body-composition and IGF-1 findings, pharmacokinetics, and how it compares to CJC-1295, sermorelin, and tesamorelin. Every quantitative claim is attributed to a study. Selectivity is the through-line. ## Start here Ipamorelin works by flipping one switch: a receptor on the pituitary gland called GHS-R1a, the same one the hunger hormone ghrelin uses [1]. Flipping it releases a pulse of growth hormone. What makes ipamorelin unusual is what it does *not* do — it leaves cortisol and prolactin alone, even at high doses [1]. For body composition, the studies show two things at once. Growth hormone signaling builds lean tissue and bone, and in rats ipamorelin grew bone even without a rise in IGF-1, the usual messenger [4]. But the same receptor also sits in appetite circuits, so ipamorelin can raise hunger and fat in animals through a separate, growth-hormone-independent route [7][8]. The sections below walk through the mechanism, the body-composition data, the pharmacokinetics, and how ipamorelin compares with the GHRH-type peptides it is often paired with. ## Mechanism: a selective ghrelin-receptor agonist Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs — the cells that make growth hormone — triggering a discrete pulse of release [1]. Mechanistically, receptor activation runs through a Gq/phospholipase-C pathway that raises intracellular calcium and drives growth-hormone secretion. The defining experiment came in 1998: in primary rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released growth hormone potently (swine ED50 of 2.3 nmol/kg, comparable to GHRP-6 at 3.9 nmol/kg) yet did not raise ACTH or cortisol above the level seen with GHRH even at doses more than 200-fold above its growth-hormone ED50 [1]. It releases growth hormone by a mechanism distinct from GHRH, which is precisely why it is combined with GHRH analogs — the two pathways are complementary rather than redundant. ## The body-composition evidence The clearest skeletal result is the 1999 bone study: subcutaneous ipamorelin at 18, 90, and 450 μg/day (divided three times daily for 15 days) raised the longitudinal bone-growth rate of adult female rats from 42 μm/day on vehicle to 44, 50, and 52 μm/day — a clean dose-response — with no measurable change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The absence of an IGF-1 change is the headline: it indicates a partly local, growth-hormone-pulse-driven skeletal effect rather than a systemic IGF-1 mechanism. On the fat and appetite side, two weeks of twice-daily subcutaneous ipamorelin raised body weight by roughly 15% in both growth-hormone-deficient (lit/lit) and growth-hormone-intact mice, with elevated fat-pad weights and serum leptin in both genotypes [7]. Because the effect appeared even in growth-hormone-deficient animals, part of ipamorelin's influence on adiposity is growth-hormone-independent. The mechanistic basis for the appetite half is well established: acute central administration of ghrelin and growth-hormone secretagogues activates hypothalamic appetite centers and induces feeding in rats [8]. A separate line of work on the growth-hormone axis and nitrogen balance provides the protein-anabolism rationale often attached to these peptides, though it is not an ipamorelin-specific efficacy demonstration [9]. Taken together: a real lean-and-bone signal, a real appetite-and-fat signal, and a body-composition outcome that depends on which one dominates in a given protocol. ## Pharmacokinetics and metabolic context In healthy male volunteers, population PK/PD modeling across five intravenous dose levels (4.21 to 140.45 nmol/kg over 15 minutes) showed dose-proportional kinetics with a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg; the growth-hormone response peaked as a single discrete pulse about 40 minutes (0.67 h) after dosing [2]. In rats, ipamorelin showed roughly 5-fold lower plasma clearance than GHRP-6, with 60 to 80% of the dose recovered intact in bile and urine and an intranasal bioavailability of about 20% — greater metabolic stability than GHRP-6, but only modest nasal absorption [11]. Metabolic state matters: in streptozotocin-diabetic mice, intravenous ipamorelin produced markedly greater growth-hormone hypersecretion (150 ± 35 µg/L) than in non-diabetic controls (62 ± 11 µg/L), alongside hepatic growth-hormone-receptor resistance and suppressed IGF-1 [10]. And ipamorelin's growth-hormone release survives glucocorticoid suppression: methylprednisolone (5.0 mg/kg/day for 8 days) did not blunt the acute growth-hormone response in rats, and the combination raised IGF-1 and improved body-weight recovery versus steroid alone [12]. ## What is ipamorelin peptide Ipamorelin is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — derived from the earlier peptide GHRP-1 by removing its central Ala-Trp dipeptide [1]. The non-natural alpha-aminoisobutyric acid (Aib) at position 1 and the D-form amino acids give it resistance to the enzymes that would otherwise chew up a normal peptide. It is not an endogenous human molecule; it mimics the action of ghrelin at the GHS-R1a receptor. Its defining property is selectivity — growth hormone up, cortisol and prolactin flat — which is what distinguishes "ipamorelin peptide" from the broader, less selective GHRP class [1]. Its medicinal-chemistry lineage is well documented: a peptidomimetic series derived from the ipamorelin scaffold reached comparable in-vivo potency (ED50 ~2 nmol/kg IV in swine) while attaining roughly 10% oral bioavailability in dogs, showing the pharmacophore could be engineered toward orally active secretagogues [13]. ## What is cjc 1295 ipamorelin "CJC-1295 ipamorelin" refers to pairing ipamorelin with CJC-1295, a long-acting GHRH analog. The rationale is mechanistic: ipamorelin acts on the ghrelin receptor (GHS-R1a), while CJC-1295 acts on the separate GHRH receptor [1]. Because the two pathways are distinct and complementary, co-administration is intended to produce a larger, more physiological growth-hormone pulse than either alone. The crucial caveat is evidentiary: the combination has never been tested in a controlled human trial for any outcome. Its support comes entirely from the separate single-agent pharmacology of each peptide, not from combination data — a point the dosage and effects pages return to. ## Ipamorelin cjc-1295 What direct evidence exists for ipamorelin cjc-1295 as a pair is preclinical and recent. A 2026 narrative review from the USC Keck School of Medicine reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model, while explicitly noting that the evidence is limited to animal studies [16]. That is the strongest combination-specific signal in the literature, and it is a single animal finding inside a review, not a human trial. For body composition specifically, no controlled human study has measured what the pair does to lean mass or fat — the combination's reputation rests on extrapolation from each component's mechanism, not on outcome data. ## Does cjc-1295 ipamorelin work It depends entirely on what "work" means. Pharmacologically, each component does what it is designed to do — ipamorelin releases growth hormone selectively [1] and CJC-1295 extends GHRH signaling — and in one murine model the pair improved muscle tetanic tension under glucocorticoid stress [16]. Clinically, there is no controlled human trial of the combination for body composition, recovery, anti-aging, or any other outcome [16]. So the defensible answer is: the mechanism is real and animal data are suggestive, but no human outcome trial has demonstrated that the combination "works" for the goals people typically pursue with it. ## Ipamorelin vs sermorelin Ipamorelin and sermorelin raise growth hormone through different receptors. Sermorelin is a GHRH analog — it acts on the GHRH receptor and was an approved drug formulation, used historically in pediatric growth assessment. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist that was never approved and acts on a completely separate pathway [1][3]. Functionally, this is why the two are often paired rather than chosen between: a GHRH analog like sermorelin and a ghrelin-receptor agonist like ipamorelin hit complementary mechanisms. Ipamorelin's distinguishing feature within any such comparison is selectivity — it raises growth hormone without the cortisol and prolactin elevation seen with less selective ghrelin-receptor peptides [1]. ## Ipamorelin vs tesamorelin Tesamorelin is a GHRH analog with an approved human indication (HIV-associated lipodystrophy) and a body of human trial data behind that use. Ipamorelin is a ghrelin-receptor agonist with no approved indication and one failed Phase 2 trial [3]. The mechanistic contrast is the same as with sermorelin — GHRH-receptor versus ghrelin-receptor — but the evidentiary contrast is sharper: tesamorelin has controlled human efficacy data for its approved use, whereas ipamorelin's human record is a single negative ileus trial and an acute pharmacokinetic study [3][2]. For body composition, that means tesamorelin's visceral-fat effect rests on human data, while ipamorelin's body-composition profile rests on rodent studies and mechanism [4][7]. --- A dark-mode evidence console for the ipamorelin record — the selective growth-hormone pulse logged where the studies confirm it, the body-composition signal read off the rodent data alone, and the single failed human trial posted in plain sight; no clinic behind the panel and nothing here dosed, sourced, or sold.